JP2016513950A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016513950A5 JP2016513950A5 JP2015533454A JP2015533454A JP2016513950A5 JP 2016513950 A5 JP2016513950 A5 JP 2016513950A5 JP 2015533454 A JP2015533454 A JP 2015533454A JP 2015533454 A JP2015533454 A JP 2015533454A JP 2016513950 A5 JP2016513950 A5 JP 2016513950A5
- Authority
- JP
- Japan
- Prior art keywords
- oligomer
- monomers
- affinity region
- region consisting
- microrna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000178 monomer Substances 0.000 claims 9
- 108700011259 MicroRNAs Proteins 0.000 claims 4
- 239000002679 microRNA Substances 0.000 claims 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261705668P | 2012-09-26 | 2012-09-26 | |
| US61/705,668 | 2012-09-26 | ||
| DKPA201200587 | 2012-09-26 | ||
| DKPA201200587 | 2012-09-26 | ||
| PCT/DK2013/050308 WO2014048441A1 (en) | 2012-09-26 | 2013-09-26 | Oligomers with improved off-target profile |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016513950A JP2016513950A (ja) | 2016-05-19 |
| JP2016513950A5 true JP2016513950A5 (enExample) | 2017-06-22 |
| JP6352269B2 JP6352269B2 (ja) | 2018-07-04 |
Family
ID=50387035
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015533454A Active JP6352269B2 (ja) | 2012-09-26 | 2013-09-26 | オフターゲットプロファイルの改善されたオリゴマー |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9725721B2 (enExample) |
| EP (1) | EP2900822B1 (enExample) |
| JP (1) | JP6352269B2 (enExample) |
| CN (1) | CN104955950B (enExample) |
| AU (1) | AU2013324716B2 (enExample) |
| CA (1) | CA2886116C (enExample) |
| WO (1) | WO2014048441A1 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX393138B (es) | 2011-04-25 | 2025-03-24 | Sanofi Sa | Compuestos de microarn y metodos para modular la actividad de mir-21. |
| MY173600A (en) | 2012-04-25 | 2020-02-08 | Sanofi Sa | Microrna compounds and methods for modulating mir-21 activity |
| US9879255B2 (en) | 2012-10-02 | 2018-01-30 | University Of Newcastle Upon Tyne | Modulation of RNA activity and vascular permeability |
| UA116639C2 (uk) | 2012-10-09 | 2018-04-25 | Рег'Юлес Терап'Ютікс Інк. | Способи лікування синдрому альпорта |
| JP2016518842A (ja) | 2013-05-01 | 2016-06-30 | レグルス セラピューティクス インコーポレイテッド | マイクロRNA化合物およびmiR−122をモジュレートする方法 |
| WO2015061536A1 (en) | 2013-10-25 | 2015-04-30 | Regulus Therapeutics Inc. | Microrna compounds and methods for modulating mir-21 activity |
| RU2017100884A (ru) * | 2014-06-13 | 2018-07-18 | Торэй Индастриз, Инк. | Набор или устройство для обнаружения рака ободочной и прямой кишки и способ обнаружения |
| JP6804975B2 (ja) * | 2014-06-13 | 2020-12-23 | 東レ株式会社 | 乳がんの検出キット又はデバイス及び検出方法 |
| EP3156503B1 (en) * | 2014-06-16 | 2019-12-11 | Toray Industries, Inc. | Stomach cancer biomarker and detection method |
| EP4613881A3 (en) | 2014-06-18 | 2025-11-19 | Toray Industries, Inc. | Liver cancer detection kit or device, and detection method |
| JP6385732B2 (ja) * | 2014-06-27 | 2018-09-05 | 国立大学法人北海道大学 | 免疫応答制御剤 |
| MA40463A (fr) | 2014-08-07 | 2017-06-14 | Regulus Therapeutics Inc | Ciblage de micro-arn pour traiter des troubles métaboliques |
| WO2016043170A1 (ja) * | 2014-09-16 | 2016-03-24 | 東レ株式会社 | miRNA発現量の比較解析方法及び装置 |
| WO2016115609A1 (en) * | 2015-01-20 | 2016-07-28 | Katholieke Universiteit Leuven | Colon cancer |
| EP3263135B1 (en) | 2015-02-25 | 2020-01-15 | Bioneer Corporation | Pharmaceutical composition for treating cancer comprising microrna as active ingredient |
| CN104826133B (zh) * | 2015-05-01 | 2020-11-24 | 北京博奥医学检验所有限公司 | 一种与肺腺癌有关的miRNA及其药物组合物 |
| CN107058473B (zh) * | 2016-11-03 | 2020-10-27 | 中国人民解放军陆军军医大学 | 一种联合miR-676、miR-181b和miR-3591诊断急性高山病的试剂盒 |
| CN107058471B (zh) * | 2016-11-03 | 2020-09-01 | 中国人民解放军陆军军医大学 | 一种通过四种microRNA生物标志物联合预测急性高山病发病风险的试剂盒 |
| CN107058470B (zh) * | 2016-11-03 | 2020-09-01 | 中国人民解放军陆军军医大学 | 一种通过联合miR-136和miR-4791预测急性高山病发病风险的诊断试剂盒 |
| CN107058472B (zh) * | 2016-11-03 | 2020-10-27 | 中国人民解放军陆军军医大学 | 一种通过四种血浆microRNA联合诊断急性高山病的诊断试剂盒 |
| CN107058474B (zh) * | 2016-11-03 | 2020-09-01 | 中国人民解放军陆军军医大学 | 一种通过血浆microRNA-3591-3p诊断急性高山病的诊断试剂盒 |
| CN107058475B (zh) * | 2016-11-03 | 2020-10-27 | 中国人民解放军陆军军医大学 | 一种联合miR-676、miR-181b和miR-193b诊断急性高山病的试剂盒 |
| CN108251422A (zh) * | 2016-12-29 | 2018-07-06 | 昆山彭济凯丰生物科技有限公司 | 通过miR-6069进行抗癌的方法和药物及其应用 |
| CN108295086B (zh) * | 2017-01-13 | 2021-11-02 | 昆山彭济凯丰生物科技有限公司 | 通过miR-4418进行抗癌的方法和药物及其应用 |
| CN108295260A (zh) * | 2017-01-13 | 2018-07-20 | 彭长庚 | 通过miR-1915-3p进行抗癌的方法和药物及其应用 |
| CN108310381A (zh) * | 2017-01-16 | 2018-07-24 | 昆山彭济凯丰生物科技有限公司 | 通过miR-6511b-3p进行抗癌的方法和药物及其应用 |
| CN107502609A (zh) * | 2017-09-08 | 2017-12-22 | 中国科学院深圳先进技术研究院 | 一种靶向cJun信号通路的miRNA及其制备方法和应用 |
| KR102070969B1 (ko) * | 2018-04-10 | 2020-01-29 | 한국한의학연구원 | 통증 판별용 마커 |
| TWI854980B (zh) | 2018-05-08 | 2024-09-11 | 美商雷格勒斯治療公司 | 用於調節mir-122之微小rna化合物及方法 |
| CN109468375B (zh) * | 2018-12-28 | 2021-05-14 | 固安博健生物技术有限公司 | 分子标志物在骨质疏松症中的应用 |
| WO2020246380A1 (ja) * | 2019-06-05 | 2020-12-10 | 株式会社キャンサーステムテック | 癌治療剤 |
| CN111073973A (zh) * | 2019-12-10 | 2020-04-28 | 石河子大学 | 一种用于早期诊断2型糖尿病的microRNA序列及其应用 |
| CN114767703B (zh) * | 2022-06-20 | 2022-09-02 | 山东恺悌生物制品有限公司 | miR-4311模拟物在制备肺癌治疗药物中的应用 |
| CN122074089A (zh) * | 2023-09-27 | 2026-05-22 | 三晟医药公司 | 新型siRNA构建体、治疗剂和修饰 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5898031A (en) * | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
| ES2344566T3 (es) * | 2003-12-23 | 2010-08-31 | Santaris Pharma A/S | Compuestos oligomericos para la modulacion de bcl-2. |
| CA2622583A1 (en) | 2005-09-15 | 2007-03-22 | Henrik Frydenlund Hansen | Rna antagonist compounds for the inhibition of apo-b100 expression |
| AU2007323469B2 (en) * | 2006-11-23 | 2014-07-24 | Guangdong Maijinjia Biotechnology Co., Ltd | Oligonucleotides for modulating target RNA activity |
| US20090137504A1 (en) * | 2006-12-21 | 2009-05-28 | Soren Morgenthaler Echwald | Microrna target site blocking oligos and uses thereof |
| CA2690643A1 (en) | 2007-06-14 | 2008-12-18 | Mirx Therapeutics Aps | Oligonucleotides for modulation of target rna activity |
| NZ585327A (en) | 2007-11-26 | 2012-10-26 | Santaris Pharma As | Lna antagonists targeting the androgen receptor |
| WO2009090182A1 (en) * | 2008-01-14 | 2009-07-23 | Santaris Pharma A/S | C4'-substituted - dna nucleotide gapmer oligonucleotides |
| US9034837B2 (en) * | 2009-04-24 | 2015-05-19 | Roche Innovation Center Copenhagen A/S | Pharmaceutical compositions for treatment of HCV patients that are poor-responders to interferon |
| WO2011115818A1 (en) * | 2010-03-17 | 2011-09-22 | Isis Pharmaceuticals, Inc. | 5'-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom |
| WO2011117353A1 (en) | 2010-03-24 | 2011-09-29 | Mirrx Therapeutics A/S | Bivalent antisense oligonucleotides |
-
2013
- 2013-09-26 CN CN201380057694.6A patent/CN104955950B/zh active Active
- 2013-09-26 US US14/431,212 patent/US9725721B2/en active Active
- 2013-09-26 JP JP2015533454A patent/JP6352269B2/ja active Active
- 2013-09-26 WO PCT/DK2013/050308 patent/WO2014048441A1/en not_active Ceased
- 2013-09-26 CA CA2886116A patent/CA2886116C/en active Active
- 2013-09-26 AU AU2013324716A patent/AU2013324716B2/en active Active
- 2013-09-26 EP EP13842025.2A patent/EP2900822B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015516989A5 (enExample) | ||
| WO2014191359A9 (en) | Aptamers and use of the aptamers in the diagnosis and treatment of cancer | |
| JP2016526529A5 (enExample) | ||
| WO2015089368A3 (en) | Complement component irna compositions and methods of use thereof | |
| JP2018512041A5 (enExample) | ||
| NZ720286A (en) | Modulation of angiopoietin-like 3 expression | |
| JP2017502668A5 (enExample) | ||
| BR112017007737A2 (pt) | variantes de aav recombinantes e usos das mesmas | |
| EP3312281A3 (en) | Complement component c5 irna compositions and methods of use thereof | |
| BR112015021884A2 (pt) | vetores compreendendo sequências de polinucleotídeos de stuffer/agente de enchimento e métodos de uso | |
| CR20150236A (es) | Métodos para el tratamiento del síndrome de alport | |
| JP2014237817A5 (enExample) | ||
| EA201791986A1 (ru) | Олигонуклеотиды, соответствующие экзону 73 гена col7a1, для терапии буллезного эпидермолиза | |
| DK3294756T3 (da) | Retroviral partikel, omfattende mindst to forskellige indkapslede, ikke-virale RNA'er | |
| JP2015512855A5 (enExample) | ||
| WO2016106387A3 (en) | Nucleic acid aptamers to treat histone-induced disease states | |
| MX2021001019A (es) | Oligonucleotidos que comprenden enlace internucleosidico de fosforotritioato. | |
| CN109641831A (zh) | 单体、聚合物、制备方法及其用途 | |
| Ghorbanian et al. | Some ordered fixed point results and the property (P) | |
| JP2016108250A5 (enExample) | ||
| JP2015523858A5 (enExample) | ||
| De Luca et al. | Involutions of epicentral words | |
| WO2012134135A3 (ko) | 스페르민 공중합체 및 이를 핵산 전달체로 이용하는 유전자 치료 | |
| Sishchuk | Theoretical and methodological approaches to understanding the concept of reorganization | |
| Nicolás-Pérez | Disección submucosa endoscópica,¿ solo para endoscopistas expertos? |